Orion Pharma 2025: A year of growth, innovation and impact

Global business

Driven by strong performance and continued international expansion, 2025 marked a year of significant progress for us. Our global reach, financial results and recognition reflect our ambition to be a truly global pharmaceutical company.

Our net sales increased by 29.6% compared to the previous year.

Operating profit grew by 51.6% compared to last year.

We were honoured the award in recognition of our strong global growth, decades of scientific expertise, and commitment to innovation. The award reflects the long-term dedication of Orion’s teams to improving health worldwide.

View more 

Our goal is to be a truly global pharmaceutical company and empower people around the world to live their lives to the fullest. We are proud that our products are sold on four different continents through us or our partners.

Patient at the heart of our work

Patients are at the heart of everything we do. Across our focus areas, our work is guided by a single commitment: to build well-being with Nordic excellence in innovation and healthcare. 

200,000 prostate cancer patients treated with darolutamide globally by the end of 2025 since first marketing authorization in 2019. Darolutamide is developed jointly by Orion Pharma and Bayer.

In 2025, our medicines reached over 250,000 patients with Parkinson’s disease. Estimates are based on 2025 sales figures and defined daily doses.

In 2025, our medicines reached over 500,000 women going through the menopause on HRT. Estimates are based on 2025 sales figures and defined daily doses.

In 2025, our medicines reached over 1.5 million asthma and COPD patients using our inhalers. Estimates are based on 2025 sales figures and defined daily doses.

Securing product availability and safety

Ensuring the availability and safety of medicines is a cornerstone of our operations. Through reliable manufacturing, secure supply chains and strict adherence to GxP standards, we ensure the consistent quality and availability of our medicines.

Our domestic production of medicines and active pharmaceutical ingredients strengthens the availability of medicines in Europe, with our Oulu site being the world’s northernmost manufacturer of APIs. Through our sites in Oulu and Hanko, we produce around 30 active pharmaceutical ingredients and have a strong position in the global supply of certain products.

As a pharmaceutical supplier, Orion is committed to the uncompromising quality and safety of its products. We adhere strictly to Good Practices (GxP) in the pharmaceutical industry and expect the same from all our value chain partners. We ensure compliance through regular assessments and audits.

Research and Development

Research and development are at the core of our innovation‑driven growth. By investing in cutting‑edge science and global collaboration, we develop next‑generation therapies for patients worldwide.

We opened a Biologics Research & Development Centre in Cambridge, UK in 2025. The centre will strengthen our scientific capabilities and support our innovation-driven growth strategy by advancing next‑generation biological therapies. The new site places us at the heart of Europe’s leading biomedical hub, enabling collaboration with world‑class experts to develop future treatments for patients worldwide.

View more 

The prostate cancer drug darolutamide received U.S. FDA and EU approvals in third indication for patients with advanced prostate cancer. The Phase III ARANOTE study conducted by Orion and Bayer showed that darolutamide combined with hormonal therapy significantly prolongs the time to cancer progression.

View more 

Our innovative pharmaceutical R&D focuses on oncology and pain. At the heart of our work is the desire to improve ​quality of life and address unmet medical needs.

​Our novel therapies change the lives of patients across the globe.

View more 

Environmental responsibility

Environmental responsibility is an integral part of our operations and long‑term strategy. By reducing emissions and engaging our suppliers we work to minimize our environmental footprint.

In 2025 we advanced projects on our emissions reduction roadmap to lower the climate impacts of our own production operations. In 2025, the transition from fossil to bio-based fuel at our API plant in Oulu was completed ahead of schedule. The switch is projected to deliver an approximately 90% reduction in local CO₂ emissions from September 2025.

Orion launched an engagement programme in 2025 targeting our highest-emitting suppliers not yet aligned with the Science Based Targets initiative. In this programme, we offer support and exchange best practices and technical expertise with our suppliers. Orion commits that 78% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution will have their own science-based climate targets by 2029.

View more 

Product safety, sustainability, and usability are key considerations in our systematic work to develop our product packaging. Improvements introduced in 2025 include tubes made with recycled aluminium, optimized bottle sizes and shapes to minimize material usage, and packaging that is easier to open for patients with neurological conditions.

View more 

We aim to be one of the top ones in environmental matters within our industry.

View more 

Ethical business

The pillars of responsible business guided our work also in 2025. We closely monitored both our own operations and those of our partners and donated to those in need.

As part of its sustainability efforts, Orion wanted to support the well-being of children and youth this year by donating to Save the Children Finland, which does significant work internationally. The support helps provide food aid and support for hobbies and learning materials in Finland, and half of the donation goes to vaccinating children and treating malnutrition in Sudan.

View more 

In 2025, we conducted a total of 38 on-site sustainability audits (2024: 34) to ensure high standards across our supply chain. There were 18 critical findings identified across five different supplier audits. While three focused on local regulatory compliance and two addressed worker safety, our audits also uncovered high-risk gaps in hazardous waste management, fire and building safety systems, and labour protections – specifically concerning overtime for pregnant employees and contract worker benefits. Immediate corrective action plans were prepared by the suppliers and close verification of their implementation was followed actively by Orion.

In the pharmaceutical industry, responsible and ethical conduct is everyone's business. Orion's Code of Conduct defines our operating principles and guides our daily work – from compliance with laws and regulations to integrity and sustainability. All Orion employees regularly complete the Code of Conduct online training to keep the common rules clear and ensure that responsibility is realized in everyday actions.

The sustainability of our supply chain is an integral part of Orion’s sustainability work. We use products and services provided by partners and suppliers in more than 50 countries to develop medicines and manufacture our products. The practices of partner companies are always investigated in advance, and selected partners must commit to Orion’s Third-Party Code of Conduct, which sets out minimum standards for sustainable conduct.

People

Our people are the foundation of Orion’s long‑term success. By investing in safety, inclusion, development and recognition, we build a high‑performance culture where people can grow, thrive and make a meaningful impact.

There are altogether over 4,000 of us Orionees in over 35 different countries. Our work builds well-being, drives innovation, and impacts millions of lives around the world.

Equal opportunity and fairness are part of our heritage and shape how we work every day. We’ve been recognized by Financial Times as one of Europe’s Diversity Leaders for several years in a row – a reflection of our ongoing commitment. We’re especially proud that gender diversity is reflected across our teams, leadership, and board, and we continue to foster a workplace where everyone feels recognized and respected.

We believe that a strong safety culture is born from continuous learning. That's why our people managers organize regular safety sessions for employees, discussing various aspects of safety from multiple perspectives.

To create motivation for the increasing ambition level, support the development of a high-performance culture and accelerate strategy execution, Orion decided to increase the annual investment into short-term incentives globally by 5 million euros.

We offer our employees unique opportunities to grow and develop – both professionally and personally. We believe this creates meaningful and long-term career paths. This is also reflected in the fact that Orion careers are often exceptionally long – for many of us, spanning decades. This is why many of our recruitments are filled internally.

Our MyDevelopment discussion focuses on learning, professional growth, understanding the employee role, and feedback. They are designed to enable meaningful and impactful conversations between employee and manager on each employee’s career and development aspirations. MyDevelopment discussions took place on schedule for 92% of Orionees in 2025.

View more 

We continued to build a culture of appreciation through the Stellar recognition tool. Since its launch in September, colleagues have sent nearly 900 recognition cards to one another, celebrating everyday successes and reinforcing our shared values. By highlighting positive contributions and acknowledging great work, Stellar is helping us inspire one another and strengthen our collective energy.

Nearly 80% of Orionees took part in last autumn’s Orion Voice employee survey. At Orion Pharma, openness, trust, and collaboration are part of our DNA. We believe that when people feel heard, supported, and inspired, they can do work that truly matters.